High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition

Abstract excerpt

// Laurel T. Bate-Eya 1 , Ilona J.M. den Hartog 1 , Ida van der Ploeg 1 , Linda Schild 1 , Jan Koster 1 , Evan E. Santo 1 , Ellen M. Westerhout 1 , Rogier Versteeg 1 , Huib N. Caron 2 , Jan J. Molenaar 1 , M. Emmy M. Dolman 1 1 Department of Oncogenomics, University of Amsterdam, Amsterdam, The Netherlands 2 Department of Pediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell death mechanisms and regulation
• Share to Neuroblastoma Research and Treatments
• Share to Ubiquitin and proteasome pathways